Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered Paper session: NETs and endocrine tumours

1644O - Donafenib in locally advanced/metastatic, radioactive iodine-refractory, differentiated thyroid cancer: A randomized, double-blind, placebo-controlled, multi-center phase III clinical trial (DIRECTION)


12 Sep 2022


Proffered Paper session: NETs and endocrine tumours


Clinical Research;  Targeted Therapy

Tumour Site

Thyroid Cancer


Yansong Lin


Annals of Oncology (2022) 33 (suppl_7): S750-S757. 10.1016/annonc/annonc1077


Y. Lin1, H. Yang2, F. Shi3, A. Yang4, X. Han5, B. Liu6, Z. Li7, Q. Ji8, L. Tang9, Z. Deng10, Y. Ding11, W. Fu12, X. Xie13, L. Li14, X. He15, Z. Lv16, L. Wu17, L. Liu17

Author affiliations

  • 1 Department Of Nuclear Medicine, Peking Union Medical College Hospital, 100730 - Beijing/CN
  • 2 Department Of Nuclear Medicine, The Affiliated Cancer Hospital of Zhengzhou University, 450008 - Zhengzhou/CN
  • 3 Department Of Nuclear Medicine, Hunan Cancer Hospital, 410013 - Changsha/CN
  • 4 Department Of Nuclear Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi' An/CN
  • 5 Department Of Nuclear Medicine, The First Affiliated Hospital of Zhengzhou University, 450052 - Zhengzhou/CN
  • 6 Department Of Nuclear Medicine, West China Hospital of Sichuan University, 610041 - Chengdu/CN
  • 7 Department Of Nuclear Medicine, The Affiliated Hospital of Xuzhou Medical University, 221000 - Xuzhou/CN
  • 8 Department Of Head And Neck Surgery, Fudan University Shanghai Cancer Center, 200032 - Shanghai/CN
  • 9 Department Of Nuclear Medicine, The First Affiliated Hospital of Nanjing Medical University, 210029 - Nanjing/CN
  • 10 Department Of Nuclear Medicine, Yunnan Cancer Hospital, 650118 - Kunming/CN
  • 11 Department Of Nuclear Medicine, The Fifth Medical Center of Chinese PLA General Hospital, 100071 - Beijing/CN
  • 12 Department Of Nuclear Medicine, Affiliated Hospital of Guilin Medical University, Guilin/CN
  • 13 Department Of Oncology, The First Affiliated Hospital of Fujian Medical University, 350005 - Fuzhou/CN
  • 14 Department Of Nuclear Medicine, Zhejiang Cancer Hospital, 310022 - Hangzhou/CN
  • 15 Department Of Medical Oncology, Cancer Hospital Chinese Academy of Medical Sciences, 100021 - Beijing/CN
  • 16 Department Of Nuclear Medicine, Shanghai Tenth People's Hospital, Tongji University School of Medicine, 200072 - Shanghai/CN
  • 17 Department Of Clinical Medicine, Suzhou Zelgen Biopharmaceuticals Co., Ltd, Suzhou/CN


Login to access the resources on OncologyPRO.

Abstract 1644O


Donafenib, an oral multi-kinase inhibitor that targets Raf/MEK/ERK, VEGFR, PDGFR, has shown potent efficacy and well-tolerated safety profile in patients with progressive locally advanced/metastatic radioactive iodine-refractory differentiated thyroid cancer (RAIR-DTC) in a phase II study. The DIRECTION study aims to evaluate the efficacy and safety of donafenib and initiated when there was no available TKI for Chinese RAIR-DTC patients.


In this randomized, double-blind, placebo-controlled, multi-center phase III trial, eligible patients were randomized (2:1) to receive donafenib (300 mg) or placebo twice daily until intolerable toxicity or disease progression. The primary endpoint was PFS, the second endpoints including ORR, OS, safety, et al.


From July 2018 to February 2021, a total of 191 patients were randomized (donafenib, 128; placebo, 63) which is the largest Chinese RAIR-DTC patients enrolled in trials so far. The primary end point was met upon pre-planned second interim analysis when 67% PFS events were observed. Donafenib significantly prolonged the median IRC-PFS than placebo (12.9 vs. 6.4 months, HR=0.39, 95% CI 0.25-0.61, p<0.0001), either in TKI-naïve subgroup (18.3 vs. 7.4 months, HR=0.45, 95% CI 0.27-0.73), or in TKI-used subgroup (11.0 vs. 3.7 months, HR=0.23, 95% CI 0.09-0.61), suggesting its potential as a second line therapy. The ORR of donafenib was higher than placebo (23.3% vs 1.7%, p=0.0002). The 18-month survival rate for donafenib vs. placebo was 88.3% vs. 73.5%, with the median overall survival not reached. Regarding the drug adherence and safety, the average daily dose of donafenib was 522 mg/day, accounting for 87.0% of the initial dose (600 mg/day), indicating its well adherence. Treatment-related adverse events (TRAEs) of Grade≥3 occurred in 56 (43.8%) patients in donafenib group, with hypertension (13.3%) and palmar-plantar erythrodysaesthesia syndrome (12.5%) the most common. No treatment-related death was observed.


Donafenib well balanced the efficacy and safety, suggesting its potential to be an alternative for patients with progressive RAIR-DTC.

Clinical trial identification


Editorial acknowledgement

Legal entity responsible for the study

The authors.


Zelgen Biopharmaceuticals Co., Ltd.


L. Wu, L. Liu: Financial Interests, Personal and Institutional, Full or part-time Employment: Suzhou Zelgen Biopharmaceuticals Co., Ltd. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.